Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Other Non Operating Income (2017 - 2025)

Fortress Biotech has reported Other Non Operating Income over the past 7 years, most recently at -$21000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$21000.0 for Q4 2025, down 31.25% from a year ago — trailing twelve months through Dec 2025 was $17.6 million (up 1235.64% YoY), and the annual figure for FY2025 was $17.6 million, up 1233.69%.
  • Other Non Operating Income for Q4 2025 was -$21000.0 at Fortress Biotech, down from $17.7 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for FBIO hit a ceiling of $17.7 million in Q3 2025 and a floor of -$1.4 million in Q4 2023.
  • Median Other Non Operating Income over the past 4 years was $293000.0 (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Other Non Operating Income: crashed 338.8% in 2023 and later soared 1550.05% in 2025.
  • Fortress Biotech's Other Non Operating Income stood at $567000.0 in 2022, then crashed by 338.8% to -$1.4 million in 2023, then skyrocketed by 98.82% to -$16000.0 in 2024, then tumbled by 31.25% to -$21000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$21000.0 (Q4 2025), $17.7 million (Q3 2025), and -$62000.0 (Q2 2025) per Business Quant data.